-Bleeding patients with acquired hemophilia are treated using bypassing agents, including recombinant factor VII, activated prothrombin complex concentrate, or recombinant porcine FVIIII with the removal of autoantibodies by immunosuppressive therapy (eg. corticosteroids, rituximab, cyclophosphamide or a combinations of these agents). This evidence concerns the gene F7 and hemophilia.